- Previous Close
0.0856 - Open
0.0850 - Bid --
- Ask --
- Day's Range
0.0850 - 0.0879 - 52 Week Range
0.0720 - 12.8000 - Volume
1,225,507 - Avg. Volume
9,962,201 - Market Cap (intraday)
4.457M - Beta (5Y Monthly) -0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
www.cero.bioRecent News: CERO
View More
Performance Overview: CERO
Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CERO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CERO
View MoreValuation Measures
Market Cap
4.42M
Enterprise Value
12.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-45.28%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.75M
Diluted EPS (ttm)
-1.1900
Balance Sheet and Cash Flow
Total Cash (mrq)
3.65M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
14.46M
Company Insights: CERO
CERO does not have Company Insights